[시장보고서]개 아토피 피부염 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향,예측(2025-2035년)

개 아토피 피부염 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향,예측(2025-2035년)

Canine Atopic Dermatitis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

상품코드 : 1706790

리서치사 : Transparency Market Research

발행일 : 2025년 02월

페이지 정보 : 영문 242 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,598,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 13,049,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,500,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

개 아토피 피부염 시장 - 조사 범위

TMR의 조사 리포트 '세계의 개 아토피 피부염 시장'은 2025-2035년의 예측 기간에 시장의 지표에 관한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사하고 있습니다. 2025년을 기준연도, 2035년을 예측연도로서 2019-2035년의 세계 개 아토피 피부염 시장의 매출과 예측을 제공합니다. 또한 2025-2035년의 세계의 개 아토피 피부염 시장의 연평균 성장률(CAGR %)도 게재하고 있습니다.

이 리포트는 광범위한 조사를 거쳐 작성되고 있습니다. 1차 조사에서는 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 메이커에 대한 인터뷰를 시행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연차보고서, 프레스 릴리스, 관련 자료 등을 참조하여 개 아토피 피부염 시장을 추측했습니다.

시장 스냅숏
2024년 시장 규모	2억 3,140만 달러
2035년 시장 규모	4억 3,100만 달러
CAGR	5.8%

세계의 개 아토피 피부염 시장의 경쟁 구도에 대해 조사하고 있습니다. 세계의 개 아토피 피부염 시장에서 사업을 운영하는 주요 기업이 식별되고, 각 기업이 다양한 속성에서 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT가 이 리포트에서 소개되고 있는 세계의 개 아토피 피부염 시장에서 플레이어의 속성입니다.

주요 국가의 헬스케어 지출 데이터
브랜드와 가격 분석
최근 진보
Porter's Five Forces 분석
주요 지역/국가에서의 규제 상황
주요 지역/국가에서의 신규 시장 참여 기업용 시장 개발 전략
공급망 분석
밸류체인 분석
PESTEL 분석
주요 잠재 고객

제6장 세계의 시장 분석과 예측 : 제품 유형별

서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 제품 유형별, 2020-2035년
- 글루코코르티코이드
- 면역억제제
- 모노클로널 항체
- 칼시뉴린 저해제
- 야누스 키나아제(JAK) 저해제
- 기타
제품 유형별 시장의 매력

제7장 세계의 시장 분석과 예측 : 투여 경로별

서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 투여 경로별, 2020-2035년
- 국소
- 경구
- 주사제
투여 경로별 시장의 매력

제8장 세계의 시장 분석과 예측 : 유통 채널별

서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 유통 채널별, 2020-2035년
- 동물병원과 진료소
- 동물용 약국·드러그스토어
- E-Commerce
- 기타
유통 채널별 시장의 매력

제9장 세계의 시장 분석과 예측 : 지역별

주요 조사 결과
시장 금액 예측 : 지역별
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
국가·지역별 시장의 매력

제10장 북미의 시장 분석과 예측

미국
캐나다

제11장 유럽의 시장 분석과 예측

독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역

제12장 아시아태평양의 시장 분석과 예측

중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양

제13장 라틴아메리카의 시장 분석과 예측

브라질
멕시코
아르헨티나
칠레
페루
콜롬비아
기타 라틴아메리카 지역

제14장 중동 및 아프리카의 시장 분석과 예측

GCC 국가
남아프리카공화국
기타 중동 및 아프리카

제15장 경쟁 구도

시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 : 기업별(2024년)
기업 개요
- Zoetis
- Merck & Co., Inc.
- Elanco or its affiliates.
- Boehringer Ingelheim International GmbH
- Virbac Corporation
- Vetoquinol
- TORAY INDUSTRIES, INC.
- Biocelix
- Dechra Pharmaceuticals PLC
- Bioiberica S.A.U
- Ceva
- Bimeda Corporate
- Other prominent players

KSA

영문 목차

영문목차

Canine Atopic Dermatitis Market - Scope of Report

TMR's report on the global canine atopic dermatitis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global canine atopic dermatitis market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global canine atopic dermatitis market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the canine atopic dermatitis market.

Market Snapshot
Market Value in 2024	US$ 231.4 Mn
Market Value in 2035	US$ 431 Mn
CAGR	5.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global canine atopic dermatitis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global canine atopic dermatitis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global canine atopic dermatitis market.

The report delves into the competitive landscape of the global canine atopic dermatitis market. Key players operating in the global canine atopic dermatitis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global canine atopic dermatitis market profiled in this report.

Key Questions Answered in Global canine atopic dermatitis Market Report:

What is the sales/revenue generated by canine atopic dermatitis across all regions during the forecast period?
What are the opportunities in the global canine atopic dermatitis market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Canine Atopic Dermatitis Market - Research Objectives and Research Approach

The comprehensive report on the global canine atopic dermatitis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global canine atopic dermatitis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global canine atopic dermatitis market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Canine Atopic Dermatitis Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Canine Atopic Dermatitis Market Analysis and Forecasts, 2020-2035
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Healthcare Expenditure Data across Key Countries
5.2. Brand and Pricing Analysis
5.3. Recent Advancements in Canine Atopic Dermatitis
5.4. PORTER's Five Forces Analysis
5.5. Regulatory Landscape across Key Regions / Countries
5.6. Go-to-Market Strategy for New Market Entrants across Key Regions / Countries
5.7. Supply Chain Analysis
5.8. Value Chain Analysis
5.9. PESTLE Analysis
5.10. Key Potential Customers

6. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Product Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2020-2035
- 6.3.1. Glucocorticoids
- 6.3.2. Immunosuppressants
- 6.3.3. Monoclonal Antibodies
- 6.3.4. Calcineurin Inhibitors
- 6.3.5. Janus kinase (JAK) Inhibitor
- 6.3.6. Others
6.4. Market Attractiveness By Product Type

7. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Route of Administration

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Route of Administration, 2020-2035
- 7.3.1. Topical
- 7.3.2. Oral
- 7.3.3. Injectable
7.4. Market Attractiveness By Route of Administration

8. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2020-2035
- 8.3.1. Veterinary Hospitals and Clinics
- 8.3.2. Veterinary Pharmacies & Drug Stores
- 8.3.3. E-commerce
- 8.3.4. Others
8.4. Market Attractiveness By Distribution Channel

9. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Region

9.1. Key Findings
9.2. Market Value Forecast By Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region

10. North America Canine Atopic Dermatitis Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast By Product Type, 2020-2035
- 10.2.1. Glucocorticoids
- 10.2.2. Immunosuppressants
- 10.2.3. Monoclonal Antibodies
- 10.2.4. Calcineurin Inhibitors
- 10.2.5. Janus kinase (JAK) Inhibitor
- 10.2.6. Others
10.3. Market Value Forecast By Route of Administration, 2020-2035
- 10.3.1. Topical
- 10.3.2. Oral
- 10.3.3. Injectable
10.4. Market Value Forecast By Distribution Channel, 2020-2035
- 10.4.1. Veterinary Hospitals and Clinics
- 10.4.2. Veterinary Pharmacies & Drug Stores
- 10.4.3. E-commerce
- 10.4.4. Others
10.5. Market Value Forecast By Country, 2020-2035
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Product Type
- 10.6.2. By Route of Administration
- 10.6.3. By Distribution Channel
- 10.6.4. By Country

11. Europe Canine Atopic Dermatitis Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Product Type, 2020-2035
- 11.2.1. Glucocorticoids
- 11.2.2. Immunosuppressants
- 11.2.3. Monoclonal Antibodies
- 11.2.4. Calcineurin Inhibitors
- 11.2.5. Janus kinase (JAK) Inhibitor
- 11.2.6. Others
11.3. Market Value Forecast By Route of Administration, 2020-2035
- 11.3.1. Topical
- 11.3.2. Oral
- 11.3.3. Injectable
11.4. Market Value Forecast By Distribution Channel, 2020-2035
- 11.4.1. Veterinary Hospitals and Clinics
- 11.4.2. Veterinary Pharmacies & Drug Stores
- 11.4.3. E-commerce
- 11.4.4. Others
11.5. Market Value Forecast By Country, 2020-2035
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Spain
- 11.5.5. Italy
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Product Type
- 11.6.2. By Route of Administration
- 11.6.3. By Distribution Channel
- 11.6.4. By Country

12. Asia Pacific Canine Atopic Dermatitis Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Product Type, 2020-2035
- 12.2.1. Glucocorticoids
- 12.2.2. Immunosuppressants
- 12.2.3. Monoclonal Antibodies
- 12.2.4. Calcineurin Inhibitors
- 12.2.5. Janus kinase (JAK) Inhibitor
- 12.2.6. Others
12.3. Market Value Forecast By Route of Administration, 2020-2035
- 12.3.1. Topical
- 12.3.2. Oral
- 12.3.3. Injectable
12.4. Market Value Forecast By Distribution Channel, 2020-2035
- 12.4.1. Veterinary Hospitals and Clinics
- 12.4.2. Veterinary Pharmacies & Drug Stores
- 12.4.3. E-commerce
- 12.4.4. Others
12.5. Market Value Forecast By Country, 2020-2035
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Product Type
- 12.6.2. By Route of Administration
- 12.6.3. By Distribution Channel
- 12.6.4. By Country

13. Latin America Canine Atopic Dermatitis Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2020-2035
- 13.2.1. Glucocorticoids
- 13.2.2. Immunosuppressants
- 13.2.3. Monoclonal Antibodies
- 13.2.4. Calcineurin Inhibitors
- 13.2.5. Janus kinase (JAK) Inhibitor
- 13.2.6. Others
13.3. Market Value Forecast By Route of Administration, 2020-2035
- 13.3.1. Topical
- 13.3.2. Oral
- 13.3.3. Injectable
13.4. Market Value Forecast By Distribution Channel, 2020-2035
- 13.4.1. Veterinary Hospitals and Clinics
- 13.4.2. Veterinary Pharmacies & Drug Stores
- 13.4.3. E-commerce
- 13.4.4. Others
13.5. Market Value Forecast By Country, 2020-2035
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Argentina
- 13.5.4. Chile
- 13.5.5. Peru
- 13.5.6. Colombia
- 13.5.7. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Product Type
- 13.6.2. By Route of Administration
- 13.6.3. By Distribution Channel
- 13.6.4. By Country

14. Middle East & Africa Canine Atopic Dermatitis Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Product Type, 2020-2035
- 14.2.1. Glucocorticoids
- 14.2.2. Immunosuppressants
- 14.2.3. Monoclonal Antibodies
- 14.2.4. Calcineurin Inhibitors
- 14.2.5. Janus kinase (JAK) Inhibitor
- 14.2.6. Others
14.3. Market Value Forecast By Route of Administration, 2020-2035
- 14.3.1. Topical
- 14.3.2. Oral
- 14.3.3. Injectable
14.4. Market Value Forecast By Distribution Channel, 2020-2035
- 14.4.1. Veterinary Hospitals and Clinics
- 14.4.2. Veterinary Pharmacies & Drug Stores
- 14.4.3. E-commerce
- 14.4.4. Others
14.5. Market Value Forecast By Country, 2020-2035
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Product Type
- 14.6.2. By Route of Administration
- 14.6.3. By Distribution Channel
- 14.6.4. By Country

15. Competitive Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2024)
15.3. Company Profiles
- 15.3.1. Zoetis
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Financial Overview
  - 15.3.1.3. Product Portfolio
  - 15.3.1.4. Business Strategies
  - 15.3.1.5. Recent Developments
- 15.3.2. Merck & Co., Inc.
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Financial Overview
  - 15.3.2.3. Product Portfolio
  - 15.3.2.4. Business Strategies
  - 15.3.2.5. Recent Developments
- 15.3.3. Elanco or its affiliates.
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Financial Overview
  - 15.3.3.3. Product Portfolio
  - 15.3.3.4. Business Strategies
  - 15.3.3.5. Recent Developments
- 15.3.4. Boehringer Ingelheim International GmbH
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Financial Overview
  - 15.3.4.3. Product Portfolio
  - 15.3.4.4. Business Strategies
  - 15.3.4.5. Recent Developments
- 15.3.5. Virbac Corporation
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Financial Overview
  - 15.3.5.3. Product Portfolio
  - 15.3.5.4. Business Strategies
  - 15.3.5.5. Recent Developments
- 15.3.6. Vetoquinol
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Financial Overview
  - 15.3.6.3. Product Portfolio
  - 15.3.6.4. Business Strategies
  - 15.3.6.5. Recent Developments
- 15.3.7. TORAY INDUSTRIES, INC.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Financial Overview
  - 15.3.7.3. Product Portfolio
  - 15.3.7.4. Business Strategies
  - 15.3.7.5. Recent Developments
- 15.3.8. Biocelix
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Financial Overview
  - 15.3.8.3. Product Portfolio
  - 15.3.8.4. Business Strategies
  - 15.3.8.5. Recent Developments
- 15.3.9. Dechra Pharmaceuticals PLC
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Financial Overview
  - 15.3.9.3. Product Portfolio
  - 15.3.9.4. Business Strategies
  - 15.3.9.5. Recent Developments
- 15.3.10. Bioiberica S.A.U
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Financial Overview
  - 15.3.10.3. Product Portfolio
  - 15.3.10.4. Business Strategies
  - 15.3.10.5. Recent Developments
- 15.3.11. Ceva
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Financial Overview
  - 15.3.11.3. Product Portfolio
  - 15.3.11.4. Business Strategies
  - 15.3.11.5. Recent Developments
- 15.3.12. Bimeda Corporate
  - 15.3.12.1. Company Overview
  - 15.3.12.2. Financial Overview
  - 15.3.12.3. Product Portfolio
  - 15.3.12.4. Business Strategies
  - 15.3.12.5. Recent Developments
- 15.3.13. Other prominent players
  - 15.3.13.1. Company Overview
  - 15.3.13.2. Financial Overview
  - 15.3.13.3. Product Portfolio
  - 15.3.13.4. Business Strategies
  - 15.3.13.5. Recent Developments